Bupivacaine hydrochloride topical - Grace Therapeutics

Drug Profile

Bupivacaine hydrochloride topical - Grace Therapeutics

Alternative Names: GTX 101 - Grace Therapeutics; GTX101

Latest Information Update: 02 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Grace Therapeutics
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Postherpetic neuralgia

Most Recent Events

  • 02 Apr 2018 Chemical structure information added
  • 02 Apr 2018 Grace Therapeutics has patents pending for Bupivacaine hydrochloride topical with Patent Corporation Treaty and World International Patent Organisation
  • 02 Apr 2018 Clinical trials in Postherpetic neuralgia in USA (Topical) (Grace Therapeutics pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top